We discuss our recent findings on the increase, in chronic myeloid leukemia patients treated with imatinib, of B1 lymphocytes producing IgM anti-O-linked sugars expressed by leukemic cells, paralleled by increased B-stimulating cytokines. We propose that one important effect of imatinib treatment is due to the remodelling of bone marrow microenvironment.
No takes yet. Share an insight, caveat, or question.
Poggi et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: